If a pharmaceutical company authorizes our institution to keep a large
residual balance and states we can use the funds to further our research
at our discretion, we believe the funds have to be reclassified as a
gift restricted to research expenses.  Does anyone have any experience
with this?

Kim Babbie
518-262-5496
Albany Medical Center

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================